Clinical trials
NPC clinical trials
Below are recruiting npc clinical trials, each written for real people, not researchers. We’re tracking 77 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07311772RecruitingPhase 3
Testing houyanqing liquid for mouth sores during radiation
This trial tests a liquid medicine (houyanqing) to prevent or treat mouth sores caused by radiation therapy for nasopharyngeal cancer. You swish it in your mouth during radiation to see if it helps reduce pain and healing time.
Beijing, Beijing MunicipalityAges 18–75 - NCT07232680Recruiting
Immune profile study for nasopharyngeal cancer patients
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
Taoyuan City, TaiwanAges 18 years+ - NCT07496190RecruitingPhase 2
Becotatug Vedotin for advanced nasopharyngeal cancer not responding well to initial treatment
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
Guangzhou, GuangdongAges 18–70 - NCT06846450RecruitingPhase 3
Comparing radiation types for nasopharyngeal cancer
This trial compares two types of radiation therapy (IMRT or IMPT plus CIRT) to see which works better for patients with nasopharyngeal cancer that hasn't spread. It's for people who have not had radiation to the head or neck before.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06788002RecruitingPhase 2
Low-dose radiation and chemoimmunotherapy for NPC with liver spread
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
Changsha, HunanAges 18–70 - NCT06829147Recruiting
AI to diagnose lymph node spread in nasopharyngeal cancer
This trial tests whether a computer model can accurately detect if cancer has spread to lymph nodes in patients with nasopharyngeal carcinoma. It uses MRI and PET/CT scans taken before treatment to see if the AI can replace or supplement current methods.
Guangzhou, GuangdongAges Any age - NCT06982300RecruitingPhase 1/Phase 2
PET scan for advanced nasopharyngeal cancer
This trial tests a special PET scan that can detect a receptor (SSTR2) on cancer cells to see if it can help guide treatment for people with nasopharyngeal cancer (a type of head and neck cancer). It may help doctors choose the best therapy for you.
GroningenAges 18 years+ - NCT07101744RecruitingPhase 2
Drug combination study for advanced nasopharyngeal cancer
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
GuangdongAges 18–70 - NCT07303023RecruitingPhase 3
Personalized neck radiation to prevent cancer spread
This trial tests whether a personalized radiation plan for the neck can prevent cancer from spreading in people with nasopharyngeal carcinoma. It's for those whose cancer hasn't spread beyond the head and neck area.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07325539RecruitingPhase 2
Radiation and immunotherapy with chemo for nose and throat cancer
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–65 - NCT07459296RecruitingPhase 3
Becotatug vedotin plus sintilimab for advanced nasopharyngeal cancer
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
Nanning, GuangxiAges 18–70 - NCT07618078Recruiting
Personalized Cancer Risk Assessment for Nasopharyngeal Cancer
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
Beijing, Beijing MunicipalityAges 18–75 - NCT07137052Recruiting
Precise adaptive radiotherapy for nasopharyngeal cancer
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for nasopharyngeal cancer. It is designed for patients who have not yet had any treatment and whose cancer is limited to the head and neck area.
XiamenAges 18–70 - NCT07781358RecruitingPhase 2
Testing a new drug combination for recurrent nasopharyngeal cancer
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06064097RecruitingPhase 2
Nivolumab plus chemo for young people with nasopharyngeal cancer
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Birmingham, AlabamaAges Up to 21 years - NCT07762976RecruitingPhase 2
Tailoring chemo for nasopharyngeal cancer using EBV-DNA and MRI
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06669611RecruitingPhase 3
Comparing two drug combos for advanced nasopharyngeal cancer
This trial tests whether a new drug combination (Nab-Paclitaxel with Camrelizumab) works better than the standard GP chemotherapy plus Camrelizumab for people whose nasopharyngeal cancer has come back or spread. The goal is to find a more effective treatment option.
Guangzhou, GuangdongAges 18 years+ - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75 - NCT07690787RecruitingPhase 2
Study of JS207 for nasopharyngeal cancer
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
Hong KongAges 18 years+ - NCT06282497Recruiting
New radiation technique to reduce dry mouth in nasopharyngeal cancer
This trial compares a new radiation technique designed to reduce dry mouth (xerostomia) with standard radiation for people with nasopharyngeal cancer. It aims to see if the new approach can protect saliva glands while still treating the cancer effectively.
Zhongshan, GuangdongAges 18–70 - NCT07154069RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer after chemo
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Guangzhou, GuangdongAges 18–65 - NCT05397769RecruitingPhase 2
Test envafolimab with chemoradiation for advanced nasopharyngeal cancer
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
Guangzhou, GuangdongAges 18–65 - NCT07528183RecruitingPhase 2
Immunotherapy after chemo and radiation for recurrent nose cancer
This trial tests whether maintenance immunotherapy (PD-1 inhibitor) followed by delayed salvage radiation therapy can help keep your cancer under control after you have already responded to initial chemo-immunotherapy. It is for people with recurrent nasopharyngeal carcinoma that has come back in the nose or neck area, but has not spread to distant organs.
Fuzhou, FujianAges 18–70 - NCT06831357Recruiting
Predicting Cancer Spread in Nasopharyngeal Cancer Using AI
This trial uses a deep learning computer model to look at tissue images and MRI scans to predict whether nasopharyngeal carcinoma may spread to other parts of the body. It may help doctors decide on the best treatment for people with certain stages of this cancer.
Guangzhou, GuangdongAges Any age
Hear when a new NPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for npc?
- Yes. Clin2 currently lists 77 recruiting npc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a npc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a npc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.